Get the Daily Brief
Latest Biotech News
Novartis pays $165m for SciNeuro brain‑shuttle; big‑ticket milestones possible
Novartis licensed a preclinical amyloid‑targeting brain‑shuttle program from SciNeuro for $165 million upfront with as much as $1.5 billion in additional milestones. The collaboration aims to...
Asimov licenses LV Edge to AGC Biologics – simplifies lentiviral manufacturing
Asimov and AGC Biologics struck a licensing deal to deploy Asimov’s LV Edge Packaging cell line at AGC’s Milan Cell & Gene Center of Excellence. The LV Edge system uses an engineered HEK293 line...
AbbVie pays $650M upfront for PD-1/VEGF asset — Global rights ex‑China
AbbVie announced an exclusive licensing deal with China’s RemeGen to develop, manufacture and commercialize RC148, a PD‑1/VEGF bispecific antibody. AbbVie paid $650 million up front and can...
Lilly and Nvidia commit $1B to AI drug‑discovery lab — five‑year pact
Eli Lilly and Nvidia announced a five‑year, up to $1 billion collaboration to build a San Francisco AI laboratory focused on accelerating drug discovery. The partnership combines Lilly’s...
Illumina unveils Billion Cell Atlas; Tahoe joins large single‑cell push
Illumina launched its Billion Cell Atlas initiative, releasing massive single‑cell perturbation data across ~200 cell lines and aiming for one billion cells by year‑end. The company said the atlas...
AI designs programmable gene insertion — Basecamp’s EDEN demonstrates breadth
Basecamp Research said its EDEN family of evolutionary AI models can design therapeutic molecules that enable programmable insertion of large DNA sequences into precise genomic locations across...
FDA eases manufacturing oversight for cell and gene therapies — CBER guidance
The U.S. Food and Drug Administration outlined steps to relax and modernize manufacturing and quality expectations for cell and gene therapies, signaling increased regulatory flexibility to...
Large raises and funds: Parabilis nets $305M; Arkin closes $100M early‑stage fund
Parabilis Medicines closed a $305 million Series F to advance zolucatetide (FOG‑001) toward Phase III for desmoid tumors; the company said the financing sparked IPO speculation. Parabilis...
Restructuring wave: Tessera cuts 35% as it pivots; Lyra halts development, shutters ops
Tessera Therapeutics announced permanent layoffs affecting roughly 35% of staff (about 90 employees) as it shifts focus to a gene‑editing collaboration with Regeneron and prioritizes an in‑vivo...
Scale and automation in CGT manufacturing — Asimov licenses LV Edge; Trenchant shows AutoCell data
Asimov licensed its LV Edge Packaging lentiviral production cell line to CDMO AGC Biologics, enabling single‑plasmid transfection workflows and reducing GMP plasmid costs, supply‑chain risk and...
Oncology diagnostics surge: Natera and Guardant report double‑digit growth in testing
Natera reported preliminary Q4 revenue driven by Signatera MRD test sales and processed over 923,600 tests in Q4, with oncology and MRD volumes up substantially year‑over‑year; the company guided...
Targeted therapies advance: FLOWERS shows osimertinib combinations; MOUNTAINEER confirms tucatinib benefit
The FLOWERS Phase 2 trial, published in Nature Communications, reported that osimertinib with or without savolitinib showed efficacy in EGFR‑mutant NSCLC patients with MET aberrations, providing...
AbbVie jumps into PD‑1xVEGF sweepstakes: $650M upfront, multibillion milestones loom
AbbVie struck an exclusive out‑of‑China license for RemeGen’s PD‑1×VEGF bispecific, paying $650 million up front with total deal value reported in the billions contingent on milestones. The...
Nvidia and Lilly double down on AI: $1B lab to accelerate drug discovery
Nvidia and Eli Lilly announced a joint investment — roughly $1 billion over five years — to build a San Francisco AI drug‑discovery lab that will pair Lilly’s biological and clinical data with...
Basecamp’s EDEN model... programmable gene insertion demonstrated at scale
Basecamp Research reported that its EDEN family of evolutionary AI models can design programmable gene‑insertion tools that place large therapeutic DNA sequences at precise genomic sites. In...
Big single‑cell dataset pact: Tahoe, Arc and Biohub pledge multimillion commitments
Tahoe Therapeutics, the Arc Institute, and Biohub announced a collaborative effort to generate an expansive single‑cell perturbation dataset—over 120 million cells across some 225,000 drug–patient...
Engineered skin as a living monitor: implanted graft signals inflammation
A Japanese research consortium led by Tokyo City University and the University of Tokyo described an implanted engineered skin "living sensor display" that fluoresces in response to internal...
FDA eases CGT controls: CBER details greater flexibility for manufacturing and CMC
The U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER) published guidance outlining relaxed chemical, manufacturing and control (CMC) expectations for certain...
AutoCell promises dramatic CGT scale‑up: Trenchant shows prototype data
Trenchant Biosystems released internal and external validation data for its AutoCell automated cell‑and‑gene‑therapy (CGT) manufacturing prototype, reporting a reduction of vein‑to‑vein timelines...
Lyra halts LYR‑210 program and lays off staff: Board opts for strategic alternatives
Lyra Therapeutics announced it will suspend development of LYR‑210 for chronic rhinosinusitis and implement a workforce reduction that impacts its remaining employees. The board elected to cease...